Haematological cancer patients are positive towards gene testing

Mia Sommer(Aalborg University Hospital), Rasmus Froberg Brøndum(Aarhus University), Charles Vesteghem(Aalborg University Hospital), Tarec Christoffer El‐Galaly(Aalborg University Hospital), Hans Erik Johnsen(Herlev Hospital), Martin Bøgsted(Chr. Hansen (Denmark)), Marlene Maria Nielsen(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital)
VBN Forskningsportal (Aalborg Universitet)
May 30, 2018
Cited by 1

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
|Blood|2009|390
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Leukemia|2012|362
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
|Leukemia|2015|256